Three dose levels entered a randomized expansion cohort; only one came out with a Phase 3 ticket. SystImmune and Bristol Myers Squibb will present at WCLC in Seoul on September 14 showing that 2.5 mg/kg dosed on days one and eight of a three-week cycle produced higher efficacy than the lower doses tested, with a safety profile the investigators judged manageable, and that result locks in the dose for IZABRIGHT-Lung01, the registrational study of iza-bren in EGFR-mutated NSCLC after progression on a third-generation EGFR inhibitor.
The importance of that population context is worth sitting with. Osimertinib is the dominant third-generation EGFR inhibitor, and FDA-approved in both first and adjuvant settings, which means a large and growing share of metastatic EGFR-mutated patients will eventually need a next option. The FDA recognized that gap when it granted iza-bren Breakthrough Therapy Designation in August 2025 for patients with EGFR exon 19 deletions or exon 21 L858R mutations whose disease had progressed on a prior EGFR inhibitor.
What the WCLC data add is a global dimension. Earlier efficacy and safety signals for iza-bren came primarily from Chinese patient cohorts; the Phase 1 randomized expansion presented by Alexander Spira enrolled a global population and showed consistency with those earlier results. That matters for a registrational strategy: regulators in the U.S. and Europe typically want to see their own patient populations represented before an approval package is assembled. Confirming the profile holds internationally is a prerequisite, not a formality, for IZABRIGHT-Lung01 to support a broad label.
Iza-bren targets both EGFR and HER3, two receptors that drive proliferation in epithelial cancers, and couples that bispecific antibody to a topoisomerase I inhibitor payload. The dual-targeting design is the rationale for calling it potentially first-in-class as an EGFRxHER3 ADC, though that designation ultimately depends on what reaches approval first. The concrete question now is whether the 2.5 mg/kg dose holds its efficacy advantage over the full breadth of the IZABRIGHT-Lung01 enrollment, where patient heterogeneity and longer follow-up will test what the expansion cohort suggested.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
